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Abstract. Over the past decade, matrix-assisted laser desorption/
ionization time‑of‑flight mass spectrometry (MALDI‑TOF MS) 
has been established as a valuable platform for microbial identi-
fication, and it is also frequently applied in biology and clinical 
studies to identify new markers expressed in pathological condi-
tions. The aim of the present study was to assess the potential 
of using this approach for the classification of cancer cell lines 
as a quantifiable method for the proteomic profiling of cellular 
organelles. Intact protein extracts isolated from different 
tumor cell lines (human and murine) were analyzed using 
MALDI‑TOF MS and the obtained mass lists were processed 
using principle component analysis (PCA) within Bruker 
Biotyper® software. Furthermore, reference spectra were 
created for each cell line and were used for classification. Based 
on the intact protein profiles, we were able to differentiate and 
classify six cancer cell lines: two murine melanoma (B16‑F0 
and B164A5), one human melanoma (A375), two human breast 
carcinoma (MCF7 and MDA‑MB‑231) and one human liver 
carcinoma (HepG2). The cell lines were classified according to 
cancer type and the species they originated from, as well as by 
their metastatic potential, offering the possibility to differentiate 
non-invasive from invasive cells. The obtained results pave the 
way for developing a broad‑based strategy for the identification 
and classification of cancer cells.
Introduction
The development and application of matrix-assisted laser 
desorption/ionization time‑of‑f light mass spectrom-
etry (MALDI‑TOF MS) for the identification of microorganisms 
has been revolutionary. Microbial proteomics has attracted 
attention worldwide and this has resulted in the development 
of novel identification methods which are rapid, robust and 
relatively inexpensive (1).
For the identification of microorganisms, MALDI‑TOF MS 
analysis typically concentrates on intact proteins with a 
molecular weight in the range of 2‑20 kDa. The proteins in 
this range are mainly ribosomal proteins which represent 
approximately 30% of the total proteins from a microbial cell (2). 
Following mass spectral analysis, the raw spectra are processed 
using a peak recognition algorithm. The data generated 
following MALDI‑TOF MS analysis consist of two large sets 
of values: mass‑to‑charge (m/z) and intensity. Each m/z value 
has a corresponding intensity value. The signal extraction, also 
known as peak picking, is often corrupted by noise. Therefore, 
various algorithms have been developed for obtaining peaks that 
correspond to true peptide/proteins signals (3). This is a very 
important step in data analysis as different peak recognition 
algorithms may have a considerable effect on the peak list, and 
therefore should be adjusted with care (4). Once extracted, the 
peak lists are compared to a dedicated database which contains 
reference mass spectra of known microbial strains. The first 
such platform ‘MALDI Biotyper’ was developed by Bruker 
Daltonics. Another platform combines the Shimadzu mass 
instrumentation and software ‘Launchpad’ with a centralized 
database ‘SARAMIS’ provided by BioMerieux (Marcy l'Etoile, 
France) (1,5).
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Although mainly used for microbial identification, intact 
protein profiles have also been used successfully for the 
characterization and identification of mammalian cell lines (6‑8). 
Karger et al (6) identified 66 cell lines from 34 species using 
reference spectra library created by MALDI Biotyper, while 
Povey et al (8) used partial least squares discriminant analysis 
model to predict the phenotype of recombinant mammalian cell 
lines.
The methods currently used for the identification and 
characterization of cancer cells, namely DNA fingerprinting, 
immunohistochemistry and flow cytometry (9‑12), require 
specific reagents which limit the degree of multiplexing. In 
addition, these methods require laborious sample preparation 
which leads to an increased analysis time. The proteomic 
approach can achieve a level of multiplexing where several cell 
lines can be analyzed without changing the method parameters 
and without using specialized materials and reagents. 
The aim of this study was to assess the potential of using 
MALDI‑TOF MS for the classification of cancer cell lines. To 
achieve this, the procedure for the taxonomic classification of 
microorganisms was adapted. Six cancer cell lines (murine and 
human) were used in this study: B16‑F0 and B164A5 (murine 
melanoma cells), A375 (human melanoma), HepG2 (human 
liver carcinoma), MCF7 (human breast carcinoma) and 
MDA‑MB‑231 (human breast carcinoma). The statistical 
analysis was processed using MALDI Biotyper software. These 
data were used for a better observation of differences regarding 
the species and metastatic potential, differences well‑defined 
between the two human breast carcinoma cell lines (MCF7 and 
MDA‑MB‑231) and two murine melanoma cell lines (B16‑F0 
and B164A5). As an end point, a different cell line was applied 
for an upgraded picture: HepG2 (human liver carcinoma).
Materials and methods
Cell lines and reagents. The cancer cell lines used in the 
present study, B16‑F0 [murine melanoma; CRL‑6322™, 
American Type Culture Collection (ATCC), Manassas, VA, 
USA], B16 melanoma 4A5 (murine melanoma; 94042254; 
Sigma‑Aldrich Chemie GmbH, Munich, Germany), A375 
(human melanoma; CRL‑1619™; ATCC), HepG2 (human 
liver carcinoma; HB8065™; ATCC), MCF7 (human breast 
carcinoma; HTB22™; ATCC) and MDA‑MB‑231 (human 
breast carcinoma; HTB26™; ATCC), were acquired from 
Sigma‑Aldrich Chemie GmbH and ATCC as frozen items.
The specific reagents for cell culture [Dulbecco's modi-
fied Eagle's medium (DMEM); Eagle's Minimum Essential 
Medium (EMEM)], fetal bovine serum (FBS), antibiotic 
mixture of penicillin/streptomycin, phosphate‑buffered 
saline (PBS), Trypsin/EDTA and trypan blue were acquired 
from Sigma‑Aldrich Chemie GmbH and ATCC.
Ethanol, formic acid, trifluoroacetic acid and acetoni-
trile were acquired from Sigma‑Aldrich Chemie GmbH. 
α‑cyano‑4‑hydroxycinnamic acid (Bruker HCCA matrix) 
and protein I calibration standard were acquired from Bruker 
Daltonics (Bremen, Germany).
Cell culture. The murine melanoma (B164A5 and B16‑F0), 
human melanoma (A375) and human breast carcinoma 
(MDA‑MB‑231) cell lines were cultured in DMEM with 4.5 g/l 
glucose, 2 mM L‑glutamine and supplemented with 10% FBS 
and antibiotic mixture (100 U/ml penicillin and 100 µg/ml strep-
tomycin). The human liver carcinoma (HepG2) and human breast 
carcinoma (MCF7) were cultured in EMEM, supplemented with 
10% FBS and antibiotic mixture. The cells were kept in standard 
conditions as follows: a humidified atmosphere with 5% CO2 at a 
temperature of 37˚C and were passaged every 2‑3 days.
Scratch assay. The migratory character of the tumor cells used 
in this study was examined by the means of a scratch assay. 
In brief, 2x105 cells/well were seeded in 12‑well plates in 
specific culture medium and when the confluence was appro-
priate (85‑90%) a gap/scratch was drawn in the middle of the 
well with a 10 µl tip (13). The capacity of the cells to migrate 
and fill the gap was monitored for 24 h by acquiring images 
at different time points, namely 0, 3 and 24 h using an Optika 
Microscopes Optikam Pro Cool 5 and Optika View (Optika, 
Ponteranica, Italy).
Protein extraction for MALDI‑TOF MS analysis. Sample 
preparation for MALDI‑TOF MS analysis was performed as 
follows: the culture medium was discarded from the flasks; the 
cells were washed with 10 ml PBS and were subsequently incu-
bated with 3 ml 0.025% trypsin/EDTA for 3‑5 min. The reaction 
was terminated by the addition of 10 ml cell culture medium. 
The cells were stained with trypan blue and the cell number 
was established using the Neubauer cell counting chamber. 
The suspension was subsequently centrifuged at 1,700 x g 
for 5 min. The supernatant was discarded and the cell pellet 
was mixed with 1 ml of ethanol. Following centrifugation at 
1,700 x g for 5 min, the ethanol was removed and the pellet was 
reconstituted in 70% formic acid at a ratio of 20 µl/1x106 cells. 
The mixture was left at room temperature for 2 min, and then 
an equal volume of acetonitrile was added. The samples were 
then centrifuged at 10,000 x g for 5 min. An aliquot (1 µl) of the 
supernatant was spotted in duplicate onto the MTP 384 ground 
steel MALDI target plate (Bruker Daltonics). The sample was 
allowed to dry at ambient temperature and then overlaid with 
1 µl of HCCA (5 mg/ml in a mixture of acetonitrile, water and 
trifluoroacetic acid 50:47.5:2.5% v/v).
MALDI‑TOF MS analysis. The MALDI‑TOF MS instrument 
(Bruker Daltonics) was calibrated in a positive ion linear mode 
in a mass range of 5,000‑20,000 m/z, using Bruker Protein 
Calibration Standard I containing insulin, ubiquitin I, cyto-
chrome c and myoglobin. Flex Control® (version 3.4) software 
was used to acquire the data and set the method parameters. The 
following settings were used: laser frequency, 2,000 Hz; smart-
beam, ‘4_large’; sample rate and digitiser settings, 1.25 GS/sec; 
accelerator voltage, 20.07 kW; extraction voltage, 18.87 kW; lens 
voltage, 5.58 kW; and delayed extraction, 250 nsec. The laser 
intensity was adjusted such that the highest peak in the spectrum 
was in the range of 104 arbitrary units. A 1,000 laser shots were 
used for each individual spectrum and minimum of 10 individual 
spectra (10,000 laser shots) were cumulated and saved.
Mass spectra processing. Mass spectra were processed using 
MALDI Biotyper Offline Client® software (version 3.1; Bruker 
Daltonics). The MALDI‑TOF MS spectra were analyzed using 
principle component analysis (PCA). The following parameters 
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were used for pre‑processing the spectra: mass adjustment from 
5,000 to 20,000 m/z; resolution, 1; processing method, spectra 
compressing; compressing factor, 10; smoothing method, 
‘Savitsky‑Golay’ with a frame size of 25 kDa; baseline subtrac-
tion method, multipolygon with a search window of 5 kDa in 
2 runs; spectra normalization, maximum; peak piking method, 
‘Local maximum’ with 200 maximum peaks, signal‑to‑noise 
threshold, 0.01 and window width, 25 kDa. The PCA creation 
parameters were set as follows: mass from 9,500‑12,500 m/z; 
resolution, 2 and number of principal components set to auto-
matic.
For creating main spectra (MSP) the pre‑processing 
parameters used were the same as those described for PCA 
analysis except that the mass range was 9,500 to 12,500 m/z. 
For the MSP creation method, the following parameters were 
used: maximum mass errors of each single spectrum, 2,000; 
desired mass error for the MSP, 200; desired peak frequency 
minimum, 25%; maximum desired peak number for the 
MSP, 10. For the identification method, the following param-
eters were used: frequency threshold for spectra adjusting, 50; 
frequency threshold for score calculation, 5; maximum mass 
error of raw spectrum, 2,000; desired mass tolerance of the 
adjusted spectrum, 250; furthermore accepted mass tolerance 
of a peak 600, parameter of the intensity correction func-
tion, 0.25. For creating the MSP dendrogram, the following 
parameters were used: distance measure, correlation; linkage, 
average; score threshold value for a single organism, 300; and 
score threshold value for a related organism, 0.
Results
Characteristics of tumor cell appearance in culture. The 
cell lines employed in the present study in order to be clas-
sified and differentiated at proteomic level by the means of 
MALDI‑TOF MS are illustrated in Fig. 1. It can be observed that 
the cells have different shapes, even though they originate from 
the same species [Fig. 1C (B16‑F0) and D (B164A5) murine mela-
noma] or cancer type [Fig. 1E (MCF7) and F (MDA‑MB‑231) 
human breast carcinoma]. A375 (Fig. 1A) are human amela-
notic cells with an epithelial morphology, whereas B16‑F0 and 
B164A5 (murine) are melanin producing cells with a mixture 
of spindle‑shaped and epithelial‑like cells (B16‑F0) or a 
fibroblast‑like morphology (B164A5) (Fig. 1C and D, granules 
of melanin can also be observed).
The human liver carcinoma cell line, HepG2, has an epithe-
lial morphology and the cells are strongly bonded (Fig. 1B). In 
the case of the two breast human carcinoma cell lines, MCF7 
and MDA‑MB‑231, some differences were observed in terms 
of shape (an elongated shape in the case of MDA‑MB‑231 and 
a more round one in the case of MCF7 cells), albeit both are 
described to have an epithelial morphology (Fig. 1E and F).
To delineate the differences regarding the migratory char-
acter of the tumor cells studied, we performed a wound healing 
assay/scratch assay. As shown in Fig. 2, the A375 and HepG2 
cells were not able to fill the gap drawn within 24 h, what indi-
cates a low migratory capacity.
B164A5 cells (murine melanoma) proved to be highly inva-
sive, with the gap being completely filled after 24 h. The B16‑F0 
cells also exhibited a potent migratory capacity, although to a 
lesser extent than the B164A5 cells (Fig. 3).
The comparison between the two breast carcinoma cell lines 
in terms of migratory capacity indicated that the MDA‑MB‑231 
cells were more invasive (Fig. 4).
PCA analysis. PCA three‑dimensional clustering (Fig. 5) 
revealed that the three human carcinoma cell lines (HepG2, 
MDA‑MB‑231 and MCF7) formed a distinct cluster, while the 
human (A375) and murine melanoma (B164A5 and B16‑F0) 
cell lines formed another two separate clusters.
Figure 1. The appearance of tumor cells in culture. (A) A375 (human melanoma 
cells); (B) HepG2 (human liver carcinoma cells); (C) B16‑F0 (murine melanoma 
cells); (D) B164A5 (murine melanoma cells); (E) MCF7 (breast carcinoma 
cells); and (F) MDA‑MB‑231 (breast carcinoma cells).
Figure 2. The migratory/invasive capacity of human melanoma cells (A375) 
and liver carcinoma cells (HepG2) over a period of 24 h. The contrast of the 
images was increased for better visualization.
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Within the human carcinoma cluster, and also in the 
PCA dendrogram (Fig. 6) the distance level that separated 
the breast carcinoma (MDA‑MB‑231) cell line from the liver 
carcinoma (HepG2) cell line was shorter than the distance level 
between the two breast carcinoma cell lines. The contribution 
of PC1, PC2 and PC3 was found to be 66, 24 and 7%, respec-
tively (Fig. 7).
Creation and use of MSP. All MSP (Fig. 8) were used to 
confirm the classification of cell lines. This yielded a score for 
the level of similarity (Table I).
This was also illustrated as an MSP‑based dendro-
gram (Fig. 9). A score value of 3 represents the maximum 
similarity, while 0 represent no relatedness. For individual 
MSP, the results revealed a similarity between the same types 
of cancer. The only exception was the A375 MSP, where the 
Figure 3. The migratory capacity of murine melanoma cells (B16‑F0 and 
B164A5) over a period of 24 h. The contrast of the images was increased for 
better visualization.
Figure 4. The migratory capacity of human breast carcinoma cells (MCF7 and 
MDA‑MB‑231) over a period of 24 h. The contrast of the images was increased 
for better visualization.
Figure 5. PCA spectra clustering using 9,500‑12,500 m/z interval. The top left 
score plot is a 3D plot of PC1 vs. PC2 vs. PC3 while on right is a 2D plots of 
PC1 vs. PC2, bottom left is PC1 vs. PC3 and bottom right PC2 vs. PC3. Each 
dot represents one spectra: 1, A375 (human melanoma); 2, HepG2 (human liver 
carcinoma); 3, B16‑F0 (murine melanoma); 4, B164A5 (murine melanoma); 
5, MCF7 (human breast carcinoma); and 6, MDA‑MB‑231 (human breast 
carcinoma). PCA, principle component analysis.
Figure 6. PCA dendogram. 1, A375 (human melanoma); 2, HepG2 (human liver 
carcinoma); 3, B16‑F0 (murine melanoma); 4, B164A5 (murine melanoma); 
5, MCF7 (human breast carcinoma); and 6, MDA‑MB‑231 (human breast carci-
noma). PCA, principle component analysis.
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second hit was a breast carcinoma. In the MSP dendrogram 
however, all three human carcinoma cell lines (HepG2, 
MDA‑MB‑231 and MCF7) were grouped in a separate subclade 
from human carcinoma A375 cells. The murine melanoma cell 
lines (B164A5 and B16‑F0) formed separate clades from all the 
human cells. In addition, within the human carcinoma clades, 
the distance level that separated the breast carcinoma cell 
line (MDA‑MB‑231) and the liver carcinoma cell line (HepG2) 
was shorter than the distance level between the two breast 
carcinoma cell lines (MCF7 and MDA‑MB‑231).
Discussion
MALDI mass spectrometry was firstly announced in the 
late 1980's by Hillenkamp and Karas (14) who developed a 
novel ionization technique that allowed the characterization 
of large biomolecules as proteins by mass spectrophotom-
eter (15). Further improvements of the initial method propelled 
MALDI‑TOF MS into the top of renowned tools for proteomic 
research. This technique is characterized by a high sensitivity, 
an ease of operation and automated capabilities, and can be 
used for the analysis of small organic or large biochemical 
compounds obtained from various sources (15,16). Apart from 
its great usability in microbial identification, MALDI‑TOF MS 
has proven to be a valuable cancer diagnostic tool, being 
applied to detect biomarkers for a plethora of cancer types, 
such as gastrointestinal cancer, lung cancer, renal and bladder 
cancer, ovarian cancer, leukemia (17), melanoma (18), breast 
carcinoma (19) and hepatic carcinoma (20).
The present study aimed to use the established Bruker 
Biotyper protocol with minimum modifications for the 
classification and differentiation of several human and murine 
cancer cell lines. The choice of HCCA matrix was also 
supported by evidence from a previous study on cell lines (6). 
The sample preparation process was very simple, rapid and 
inexpensive, and it was found that using 70% formic acid at 
a ratio of 20 µl for 1x106 cells, provided the optimal spectra 
quality. Following the addition of acetonitrile, the final ratio was 
0.025x106 cells/ml. A higher concentration of cells led to ion 
suppression, which resulted in an increased noise level and fewer 
assigned peaks, a fact previously reported by Povey et al (8). 
The formic acid extraction requires only 2 min, a method that 
is faster compared with a previous report by Povey et al (8), 
Figure 7. The contribution of three principal components to the PCA classifi-
cation. The PC1 contribution was approximately 66% while that of PC2 and 
PC3 was approximately 24 and 7%, respectively. PCA, principle component 
analysis.
Table I. The classification results obtained by comparing the 
MSP in rapport with each other.
 Individual MSP score Group MSP score
----------------------------------------------------- ---------------------------------------------------------
Cell line Score Cell group/type Score
A375
  A375 3 Human melanoma 3
  MDA‑MB‑231 1.832 Human carcinoma 2.27
  B164A5 1.405 Murine melanoma 0.641
  HepG2 1.397
  B16‑F0 1.389
  MCF7 1.344
HepG2
  HepG2 3 Human carcinoma 2.505
  MDA‑MB‑231 2.451 Human melanoma 1.397
  MCF7 2.109 Murine melanoma 1.35
  A375 1.397
  B16‑F0 1.386
  B164A5 1.003
B16‑F0
  B16‑F0 3 Murine melanoma 2.782
  B164A5 2.479 Human carcinoma 1.406
  HepG2 1.498 Human melanoma 1.389
  A375 1.389
  MDA‑MB‑231 1.329
  MCF7 1.304
B164A5
  B164A5 3 Murine melanoma 2.659
  B16‑F0 2.48 Human melanoma 1.405
  A375 1.405 Human carcinoma <0
  MCF7 1.354
  HepG2 1.003
  MDA‑MB‑231 0.641
MCF7
  MCF7 3 Human carcinoma 2.116
  HepG2 2.109 Human melanoma 1.344
  MDA‑MB‑231 1.464 Murine melanoma 1.331
  B164A5 1.354
  A375 1.344
  B16‑F0 1.304
MDA‑MB‑231
  MDA‑MB‑231 3 Human carcinoma 2.443
  HepG2 2.449 Human melanoma 1.832
  A375 1.832 Murine melanoma 0.574
  MCF7 1.466
  B164A5 1.393
  B16‑F0 1.343
The maximum score is 3. The higher the scores, the higher the rela-
tionship. MSP, main spectrum.
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where a 4‑h‑long incubation with the matrix at 3˚C was used. 
Analysis can therefore be performed using a reduced number 
of cells (250,000 cells). The analysis was performed in manual 
mode and the laser intensity was adjusted manually to obtain the 
highest signal‑to‑noise ratio. The method proved to have a very 
good shot‑to‑shot and spot‑to‑spot reproducibility correlated to 
the new application of this method in personalized medicine 
and tumor heterogeneity observation (21).
The most challenging step in this study was to estab-
lish a spectra processing method able to transform raw 
spectra (Fig. 10) into peak lists that, once processed using 
PCA algorithm, provided a realistic classification of the cell 
lines. This process involved three steps: smoothing, baseline 
subtraction and peak picking. For both smoothing and base-
line subtraction the Bruker standard parameters were used. 
However, for peak picking the ‘local maximum’ method was 
used. This method is based on using the local maxima within 
Figure 8. MSP spectra of the cancer cells. MSP were created using the 9,500‑12,500 m/z interval (Int). Each green bar represents one reference peak. Ten refer-
ence peaks were assigned for each reference spectrums. MSP, main spectra.
Figure 9. The MSP dendrogram. 1, A375 (human melanoma); 2, HepG2 
(human liver carcinoma); 3, B16‑F0 (murine melanoma); 4, B164A5 (murine 
melanoma); 5, MCF7 (human breast carcinoma); and 6, MDA‑MB‑231 (human 
breast carcinoma). MSP, main spectra.
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a defined window width (in our case 25 kDa) rather than the 
differentiation of the entire spectrum as used in the standard 
Biotyper method. This is motivated by the fact that the noise 
has different intensities at different mass ranges. A maximum 
spectra normalization was used; in this approach the most 
intense peak from each spectrum is set to a value of 1 and the 
intensity of all other signals is calculated relative to this (22). 
The signal‑to‑noise threshold was set to 0.01. Thus, in order to 
be assigned, a peak should have a relative intensity of at least 
1% of the highest peak. By combining all these parameters, we 
were able to eliminate most of the noise and artefacts from raw 
spectra which otherwise resulted in unrealistic classification of 
the cell lines.
The MALDI mass spectra consist of a type of multivariate 
data, with each mass signal defining one molecular dimen-
sion, and the process of evaluating mass spectra requires 
multivariate statistical methods that grant the differentiation of 
samples (16). A multivariate statistical method used to analyze 
MALDI spectra is the PCA. The principle of this method is 
represented by the extraction of variance within a data set, 
reducing the dimensionality of the data set while retaining 
the information present in the original data set what leads to 
spectra with similar variation characteristics that can be clus-
tered together and the differences between samples groups can 
be easily visualized in the system (16).
PCA analysis could be applied successfully on cancer 
cells by using their group spectra for the differentiation of 
pathology with a high sensitivity and selectivity (23). We began 
by performing PCA analysis using the whole mass range of 
5,000‑20,000 m/z. As in the MSP classification, this mass range 
proved to comprise too many groups of variables which contain 
redundant information and interfere with a realistic classifica-
tion. By selecting the m/z interval of 9,500‑12,500, a minimized 
profile was created which retains more meaningful peaks, and 
at the same time eliminates peaks with similar behavior. The 
restricted mass range also decreased the number of contribu-
tory principle components to three (Fig. 7).
Since the PC3 contribution to the dataset variance is low, 
the experiment could disregard it and take only the PC1/PC2 
two‑dimensional clustering into consideration, thus reducing 
the dataset to an even lower dimensional space. The PC1/PC2 
showed a closer clustering of the three human carcinomas 
and of the two murine melanomas. The human melanoma is 
plotted at a significant distance from both murine melanoma 
and human carcinoma groups (Fig. 5).
MALDI‑imaging mass spectrometry (IMS) is also used 
with PCA analysis in a similar manner as it was used in our 
study (24). In MALDI‑IMS, the PCA is used to classify cells 
in a single tissue section, while in our study it was used to 
classify different cell lines (25). The present approach can be 
used for cancer studies in combination with MALDI‑IMS. 
The combined proteomic profiles from these two approaches 
can be compared revealing further information about tumor 
complexity.
PCA analysis has been used in conjunction with Raman 
spectroscopy in a cancer study by Bodanese et al (23) for the 
successful discrimination of basal cell carcinoma and mela-
noma from normal skin biopsies. Raman spectroscopy is a 
Figure 10. Raw spectra of the cancer cells: view that displays the entire acquisition range of 5,000‑20,000 m/z.
SERAFIM et al:  CLASSIFICATION OF CANCER CELL LINES USING MALDI‑TOF MS 1103
spectroscopic technique which typically uses electromagnetic 
radiation emitted by a sample when treated with a laser (26). 
The major difference from MALDI‑TOF MS is that Raman 
microscopy does not use a laser to ablate the proteins from the 
target. Although Raman spectroscopy has proven to be a valu-
able technique, MALDI‑TOF MS is a more widely established 
as a routine technique in many laboratories (27). It does not 
require complex sample preparation and requires minimal 
training, particularly after the technique was standardized and 
validated (5).
MSP are used as an identification basis by the MALDI 
Biotyper software. MSP are a reference spectra which contain 
one or several peak lists assigned to a bacteria species or strain. 
In the Biotyper identification workflow, one MSP should contain 
a certain number of peaks. This will provide an unambiguous 
identification of an unknown organism when its mass spectrum 
is compared to the reference MSP stored in a database. The 
software generates scoring values between 0 and 3. The higher 
the score value, the higher the degree of similarity between the 
sample and the reference MSP. Apart from identification, the 
generated MSPs can be used for sample classification instead 
of raw spectra. We decided to use this system to compare the 
obtained scores to the PCA classification. In our case, the cumu-
lated spectra (10 individual spectra of 10,000 laser shots) were 
used for creating two types of MSPs: individual MSPs which 
contain the peak list for one single cell line and three group 
MSPs which contained the cumulated peak list of the three 
main groups of cancers cells: human melanoma (A375), human 
carcinoma (MDA‑MB‑231, HepG2 and MCF7) and murine 
melanoma (B164A5 and B16‑F0) cells. In this study, a combina-
tion of parameters was tested and the optimum was used for MSP 
creation. The use of the whole mass range of 5,000‑20,000 m/z, 
did not provide a realistic classification according to the type 
of cancer and the originating species. Therefore, several mass 
ranges were selected, as well as different numbers of peaks 
to be included in the MSP. A number of ten peaks from the 
9,500‑12,500 m/z interval proved to be more appropriate in 
providing realistic results.
When compared to the group MSPs, all cell lines were 
correctly attributed to their corresponding group (Table I). The 
differences between the first and second hit were substantial 
providing an unambiguous classification.
The MSP‑based dendrogram (Fig. 9) revealed similar 
results to the PCA‑based one, proving consistency between 
the two approaches. These results are in agreement with those 
described by Geiger et al (2012) in a previous study in the way 
that species relationship prevails to organ relationship, data 
obtained by using an LTQ‑Orbitrap family mass spectrometer 
with a ‘high field’ Orbitrap mass analyzer (28). In the present 
study, the species‑based relationship was stronger than the 
relationship between different types of cancer from which the 
cells originated, a fact that was revealed for the first time by 
the means of the MALDI‑TOF MS technique. In addition, the 
restricted mass range of 9,500‑12,500 m/z was not previously 
reported.
The results revealed a closer relationship between 
HepG2 (liver carcinoma) and MDA‑MB‑231 (breast carcinoma) 
than between the two breast carcinomas cell lines. This can be 
explained by a high degree of similarity between the proteomic 
profiles of the different human cancer cell lines, a fact previ-
ously reported (28). Another hypothesis for this similarity is 
the adaptation of the cells to in vitro culture which could lead 
to a clone selection based on their proliferative potential with 
the loss of the functions that are not vital (29). Although there 
were similarities between the HepG2 and MDA‑MB‑231 cell 
lines, the MSP‑based scoring system revealed that the protein 
expression was clearly distinct between the cell lines.
The distance level between the MCF7 and MDA‑MB‑231 
cell lines revealed by MSP analysis could be explained by the 
fact that, even though these cell lines have the same origin 
(pleural effusions of metastatic mammary patients), the MCF7 
cell line (non‑invasive cells) expresses specific markers for 
luminal epithelial phenotype and is employed as a model for 
estrogen receptor‑positive tumors, whereas the MDA‑MB‑231 
cell line (invasive cells) expresses mesenchymal markers 
(vimentin) and is used for estrogen receptor‑negative breast 
cancers (30). Moreover, there were observed significant 
differences between the MCF7 and MDA‑MB‑231 proteomic 
profiles (31).
In our previous study, it was shown that there are differ-
ences between B16 murine melanoma cell sublines as regard 
molecular profile and proliferation behavior, B164A5 being 
described as a highly metastatic cell line (32). Moreover, the 
human melanoma cell line, A375, proved to be a valuable asset 
in inducing reproducible animal models with primary mela-
noma (33). The classification of melanoma cells in different 
clades could be explained by the fact that they originate from 
different species (human and murine), and in addition, A375 
cells are an amelanotic primary melanoma cell line and their 
metastatic potential is lower compared to that of the murine 
melanoma cells, B164A5 and B16‑F0 (32,33).
The differences between the cancer cell lines tested 
observed by applying MALDI‑TOF MS assert the data that 
were presented after microscopic evaluation in terms of shape 
and invasive capacity.
In conclusion, although different, the two statistical 
approaches (PCA and MSP) provided similar results. The 
MSP‑based approach can be used for building groups which 
contain one cancer type or one cancer type from a given 
species. We were able to differentiate the cells according to 
cancer type (carcinoma versus melanoma) and the same cancer 
type originating from two different species (human versus mice 
melanomas). This proves that the MSP approach can be used 
not only to identify unknown samples, but also for their clas-
sification.
The results highlighted the necessity to establish mini-
mized profiles comprising a restricted mass range. The 
MALDI‑TOF acquisition method could also be improved to 
obtain maximum resolution for the newly establish mass range 
of 9,500‑12,500 m/z. We do not exclude the possibility of other 
discriminative peaks outside this range. However, this could 
not be achieved using Biotyper software which does not allow 
direct peak list editing.
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